These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25774598)

  • 1. A methodological framework for drug development in rare diseases.
    Nony P; Kurbatova P; Bajard A; Malik S; Castellan C; Chabaud S; Volpert V; Eymard N; Kassai B; Cornu C; ;
    Orphanet J Rare Dis; 2014 Nov; 9():164. PubMed ID: 25774598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A methodological framework for drug development in rare diseases. The CRESim program: Epilogue and perspectives.
    Nony P; Kassai B; Cornu C;
    Therapie; 2020 Apr; 75(2):149-156. PubMed ID: 32156422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying emerging drugs for very rare conditions.
    Miles KA; Packer C; Stevens A
    QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do we need authorized orphan drugs when compounded medications are available?
    Dooms M; Pincé H; Simoens S
    J Clin Pharm Ther; 2013 Feb; 38(1):1-2. PubMed ID: 22973866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.
    Micallef J; Boutouyrie P; Blin O
    Fundam Clin Pharmacol; 2017 Dec; 31(6):685-694. PubMed ID: 28779530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S; Compagni A; Reich MR
    Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pharmacist, rare diseases and orphan medicines].
    Nagore Induráin C; Lacalle E; Arteche L
    An Sist Sanit Navar; 2008; 31 Suppl 2():127-43. PubMed ID: 18953376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe.
    Luisetti M; Balfour-Lynn IM; Johnson SR; Miravitlles M; Strange C; Trapnell BC; van Bronswijk H; Vogelmeier C
    Respir Med; 2012 Jun; 106(6):759-68. PubMed ID: 22414566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
    Herder M
    Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.
    Maeda K; Kaneko M; Narukawa M; Arato T
    Orphanet J Rare Dis; 2017 Aug; 12(1):143. PubMed ID: 28835285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease.
    Spineli LM; Jenz E; Großhennig A; Koch A
    Orphanet J Rare Dis; 2017 Aug; 12(1):140. PubMed ID: 28814322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of orphan medicines.
    Buckley BM
    Lancet; 2008 Jun; 371(9629):2051-5. PubMed ID: 18555919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.